Intracellular Delivery of Stabilized Peptide Blocking MTDH-SND1 Interaction for Breast Cancer Suppression

Triple-negative breast
cancer is one of the most prevalent malignant
cancers worldwide. Disrupting the MTDH-SND1 protein–protein
interaction has recently been shown to be a promising strategy for
breast cancer therapy. In this work, a novel potent stabilized peptide
with a stronger binding affinity was obtained through rational structure-based
optimization. Furthermore, a sulfonium-based peptide delivery system
was established to improve the cell penetration and antitumor effects
of stabilized peptides in metastatic breast cancer. Our study further
broadens the in vivo applications of the stabilized peptides for blocking
MTDH-SND1 interaction and provides promising opportunities for breast
cancer therapy.